Glenmark receives USFDA approval for Lacosamide Tablets

25 Mar 2022 , 01:33 AM

Glenmark Pharmaceuticals Inc USA Glenmark has received final approval by the United States Food Drug Administration US FDA for its Lacosamide Tablets USP50 mg 100 mg 150 mg and 200 mg the generic version of Vimpat Tablets 50 mg 100 mg 150 mg and 200 mg of UCB Inc The company plans to launch the product immediately According to IQVIAtrade; sales data for the 12 month period ending January 2022 the Vimpat Tablets 50 mg 100 mg 150 mg and 200 mg market achieved annual sales of approximately $17 billion